GP40221 + ozempic
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics, Safety Issues, Bioequivalence
Trial Timeline
Jun 30, 2023 → May 5, 2024
NCT ID
NCT06497049About GP40221 + ozempic
GP40221 + ozempic is a phase 1 stage product being developed by GEROPHARM for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT06497049. Target conditions include Pharmacokinetics, Safety Issues, Bioequivalence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06497049 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics